Vivani Medical, Inc. (VANI) targets August 2026 for first SLIM-1 dosing

Q: When and where did Vivani Medical (VANI) present its latest investor update?

Vivani Medical presented its latest investor update on July 15, 2026 , at the Emerging Growth Conference in New York . CEO Dr. Adam Mendelsohn spoke at 4:10 p.m. Eastern Time using a slide presentation furnished to investors.

Q: Who presented for Vivani Medical (VANI) at the Emerging Growth Conference?

The slide presentation was delivered by Dr. Adam Mendelsohn , Vivani Medical’s Chief Executive Officer. He used the slides to brief attendees on the company, including the expected August 2026 timing for the first dosing of SLIM-1.

Q: Is Vivani Medical’s (VANI) July 15, 2026 presentation considered filed under the Exchange Act?

No. The company states the information in Item 7.01 and Exhibit 99.1 is furnished, not filed , and is not subject to Section 18 liability. It is only incorporated into other securities law documents if expressly referenced.

Q: Where can investors access Vivani Medical’s (VANI) July 15, 2026 slide presentation?

The slide deck is attached as Exhibit 99.1 to the company’s current report. It is described as “Vivani Medical, Inc. slide presentation dated July 15, 2026” and includes the SLIM-1 first-dosing timing update.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Vivani Medical, Inc. furnished an investor slide presentation used at the Emerging Growth Conference in New York on July 15, 2026 at 4:10 p.m. Eastern Time. The presentation, delivered by CEO Dr. Adam Mendelsohn, includes an update that the company’s first dosing of SLIM-1 is expected in August 2026.

The information in the presentation is provided under Regulation FD, is not deemed filed or subject to liability under Section 18 of the Exchange Act, and is not incorporated by reference into other securities law filings unless expressly referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Presentation date: July 15, 2026 Presentation time: 4:10 p.m. Eastern Time Expected first dosing timing: August 2026

3 metrics

Presentation date July 15, 2026 Date of Vivani Medical’s slide presentation at the Emerging Growth Conference in New York

Presentation time 4:10 p.m. Eastern Time Scheduled time of CEO Dr. Adam Mendelsohn’s conference presentation

Expected first dosing timing August 2026 Expected date for Vivani Medical’s first dosing of SLIM-1 as described in the presentation

Key Terms

Regulation FD Disclosure, Emerging growth company, incorporated by reference, Inline XBRL

4 terms

Regulation FD Disclosure regulatory

"Item 7.01. Regulation FD Disclosure. Vivani Medical, Inc. (the “Company” or “Vivani”)"

Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

Emerging growth company regulatory

"Emerging growth company Item 7.01. Regulation FD Disclosure."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

incorporated by reference regulatory

"is attached as Exhibit 99.1 and is incorporated by reference herein."

Inline XBRL technical

"Cover Page Interactive Data File (embedded within the Inline XBRL document)."

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 07/16/2026 - 08:31 AM Accepted by SEC EDGAR 07/16/2026 - 08:30 AM

FAQ

What did Vivani Medical (VANI) disclose about its SLIM-1 program?

Vivani Medical disclosed that the expected date for its first dosing of SLIM-1 is August 2026. This timing update was included in a slide presentation furnished under Regulation FD and used at the Emerging Growth Conference in New York.

When and where did Vivani Medical (VANI) present its latest investor update?

Vivani Medical presented its latest investor update on July 15, 2026, at the Emerging Growth Conference in New York. CEO Dr. Adam Mendelsohn spoke at 4:10 p.m. Eastern Time using a slide presentation furnished to investors.

Who presented for Vivani Medical (VANI) at the Emerging Growth Conference?

The slide presentation was delivered by Dr. Adam Mendelsohn, Vivani Medical’s Chief Executive Officer. He used the slides to brief attendees on the company, including the expected August 2026 timing for the first dosing of SLIM-1.

Is Vivani Medical’s (VANI) July 15, 2026 presentation considered filed under the Exchange Act?

No. The company states the information in Item 7.01 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 liability. It is only incorporated into other securities law documents if expressly referenced.

Where can investors access Vivani Medical’s (VANI) July 15, 2026 slide presentation?

The slide deck is attached as Exhibit 99.1 to the company’s current report. It is described as “Vivani Medical, Inc. slide presentation dated July 15, 2026” and includes the SLIM-1 first-dosing timing update.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 15, 2026

Vivani Medical, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-36747

02-0692322

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1350 S. Loop Road Alameda, California	94502
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (415) 506-8462

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		VANI		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Vivani Medical, Inc. (the “Company” or “Vivani”) made a presentation at the Emerging Growth Conference in New York on Wednesday, July 15, 2026 at 4:10 p.m. Eastern Time. A copy of a slide presentation that Dr. Adam Mendelsohn, Vivani’s Chief Executive Officer, used during the conference, which includes an update that the expected date for the Company’s first dosing of SLIM-1 is expected to take place in August 2026, is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein. The slide presentation speaks only as of the date of this Current Report on Form 8-K. While Vivani may elect to update the slide presentation in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, Vivani specifically disclaims any obligation to do so.

The information contained in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), as amended, or otherwise subject to the liabilities under that Section. Furthermore, the information contained in this Item 7.01 and Exhibit 99.1 shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Vivani Medical, Inc. slide presentation dated July 15, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.